D. M. Hickey

发表

Octimibate, a potent non‐prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor

T. Rink, J. Macdermot, T. Hallam, 1991, British journal of pharmacology.

CCR2B receptor antagonists: conversion of a weak HTS hit to a potent lead compound.

I. Forbes, P. Groot, R. Ife, 2000, Bioorganic & Medicinal Chemistry Letters.

Formation of indoles, isoquinolines, and other fused pyridines from azidoacrylates

C. Moody, D. M. Hickey, L. Henn, 1984 .

Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor.

D. Tew, H. Boyd, D. Dhanak, 1999, The Biochemical journal.

Use of a novel and highly selective oxytocin receptor antagonist to characterize uterine contractions in the rat.

P. Woollard, D. Brooks, J. Liddle, 2007, American journal of physiology. Regulatory, integrative and comparative physiology.

Inhibitors of CoA-independent transacylase block the movement of arachidonate into 1-ether-linked phospholipids of human neutrophils.

R. Mayer, L. Marshall, A. Fonteh, 1995, Biochemistry.

Natural product derived inhibitors of lipoprotein associated phospholipase A2, synthesis and activity of analogues of SB-253514.

H. Boyd, D. M. Hickey, I. Pinto, 2000, Bioorganic & medicinal chemistry letters.

The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.

Hung‐Yuan Cheng, Stephen A. Smith, I. Stansfield, 2002, Bioorganic & medicinal chemistry letters.

Lipoprotein-associated PLA2 inhibition--a novel, non-lipid lowering strategy for atherosclerosis therapy.

D. Tew, Stephen A. Smith, S. Smith, 2001, Farmaco.

Precipitation and 13C-NMR relaxation enhancement measurements of the interactions of bile acids with synthetic cationic bile acid derivatives, and with spin labelled fatty acids.

P. Leeson, S. Robinson, D. Reid, 1991, Chemistry and physics of lipids.

Solid phase synthesis and SAR of small molecule agonists for the GPR40 receptor.

A. Goetz, A. Peat, D. M. Hickey, 2007, Bioorganic & medicinal chemistry letters.

Primate vascular responses to octimibate, a non‐prostanoid agonist at the prostacyclin receptor

E. F. Smith, T. Rink, A. Heagerty, 1991, British journal of pharmacology.

Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.

I. E. Smith, P. Woollard, J. Liddle, 2006, Journal of medicinal chemistry.

Potent, orally active inhibitors of lipoprotein-associated phospholipase A(2): 1-(biphenylmethylamidoalkyl)-pyrimidones.

H. Boyd, Stephen A. Smith, I. Stansfield, 2002, Bioorganic & medicinal chemistry letters.

1-(Arylpiperazinylamidoalkyl)-pyrimidones: orally active inhibitors of lipoprotein-associated phospholipase A(2).

H. Boyd, I. Stansfield, S. Stanway, 2001, Bioorganic & medicinal chemistry letters.

Patent Update: Bile Acid Sequestrants: Recent Patent Applications

D. M. Hickey, G. Benson, Deirdre M.B. Hickey, 1992 .

BASE INDUCED REACTION OF AN AZETIDIN-2-ONE: FORMATION OF A NOVEL [1,4]-DIAZEPINEDIONE

D. Dhanak, R. Haltiwanger, D. M. Hickey, 2001 .

Synthesis of thyroid hormone analogues. Part 2. Oxidative coupling approach to SK&F L-94901

P. Leeson, D. M. Hickey, S. D. Carter, 1988 .

Formation of indoles, isoquinolines, and other fused pyridines from azidoacrylates

C. Moody, D. M. Hickey, L. Henn, 1984 .

Vinyl azides in heterocyclic synthesis. Part 6. Synthesis of isoquinolines by intramolecular aza-Wittig reaction

C. Moody, D. M. Hickey, C. Rees, 1987 .

Synthesis of isoquinolines by intramolecular aza-Wittig reaction

C. Moody, D. M. Hickey, A. Mackenzie, 1984 .

The identification of a potent, water soluble inhibitor of lipoprotein-associated phospholipase A2.

H. Boyd, I. Stansfield, S. Smith, 2001, Bioorganic & Medicinal Chemistry Letters.

Synthesis and properties of macrolones characterized by two ether bonds in the linker.

A. K. Forrest, D. Verbanac, S. Alihodžić, 2010, Bioorganic & medicinal chemistry.

N-1 substituted pyrimidin-4-ones: novel, orally active inhibitors of lipoprotein-associated phospholipase A2.

D. Tew, H. Boyd, I. Stansfield, 2000, Bioorganic & medicinal chemistry letters.

2-(Alkylthio)pyrimidin-4-ones as novel, reversible inhibitors of lipoprotein-associated phospholipase A2.

D. Tew, H. Boyd, I. Stansfield, 2000, Bioorganic & medicinal chemistry letters.

5-aryl-pyrazolo[3,4-b]pyridines: potent inhibitors of glycogen synthase kinase-3 (GSK-3).

M. Saunders, J. Liddle, S. Garland, 2003, Bioorganic & medicinal chemistry letters.

Efficient preparation of useful 1,2-substituted electron-deficient dienes from sulpholenes and their use in intramolecular Diels-Alder reactions : a general approach to alkaloids

S. Fearnley, D. M. Hickey, J. Leonard, 1992 .

The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.

Hung‐Yuan Cheng, Stephen A. Smith, I. Stansfield, 2003, Bioorganic & medicinal chemistry letters.

Anti-atherosclerotic effect of SB-244323, a lipoprotein associated phospholipase A2 inhibitor, in WHHL rabbits

D. Tew, H. Boyd, K. Suckling, 2000 .

5-aryl-pyrazolo[3,4-b]pyridazines: potent inhibitors of glycogen synthase kinase-3 (GSK-3).

R. Ife, D. M. Hickey, D. Haigh, 2003, Bioorganic & medicinal chemistry letters.

The discovery of GSK221149A: a potent and selective oxytocin antagonist.

Michael J Allen, John Liddle, Fabrizio Nerozzi, 2008, Bioorganic & medicinal chemistry letters.

SK&F 97426-A: a novel bile acid sequestrant with higher affinities and slower dissociation rates for bile acids in vitro than cholestyramine.

K. Suckling, S. Blanchard, D. M. Hickey, 1997, Journal of pharmaceutical sciences.

SK&F 97426-A a more potent bile acid sequestrant and hypocholesterolaemic agent than cholestyramine in the hamster.

D. M. Hickey, A. Jaxa-Chamiec, G. M. Benson, 1993, Atherosclerosis.